联用锝[^(99)Tc]亚甲基二膦酸盐、地塞米松与雷公藤多苷治疗Graves眼病  

Combination of technetium [^(99)Tc] methylenediphosphonate,dexamasone and tripterygium glucosides in treatment of Graves ophthalmopathy

作　　者：谢丹红[1] 孙辽[1] 舒晓春[1] 叶礼红[1] 沈晶[1] 鲁红云[1] 

机构地区：[1]中山大学附属第五医院内分泌科,广东珠海519000

出　　处：《中国新药与临床杂志》2007年第12期905-908,共4页Chinese Journal of New Drugs and Clinical Remedies

基　　金：2004年广东省珠海市科技局科研立项项目(PC20041043)

摘　　要：目的:评价联用锝[^(99)Tc]亚甲基二膦酸盐(^(99)Tc-MDP)、地塞米松与雷公藤多苷治疗Graves眼病的疗效。方法:60例Graves眼病病人随机分成2组,每组各30例。对照组单纯用抗甲状腺药物(ATD)治疗,治疗组在ATD治疗的基础上,采用^(99)Tc-MDP注射液(含^(99)Tc-MDP 22 mg)静脉滴注,qd,10次为一个疗程,间歇1 wk开始下一个疗程,共3个疗程,同时口服地塞米松片0.75 mg,tid,雷公藤多苷片10 mg,tid,连用3 mo。结果:治疗组总有效率87%,对照组47%,2组疗效相比差异非常显著(P<0.01)。治疗后2组FT3和FT4均明显下降(P<0.01),尤以治疗组下降更显著(P<0.01)。治疗组治疗后甲状腺球蛋白抗体(TGAb)和甲状腺过氧化物酶抗体(TPOAh)水平明显下降,与治疗前比较,差异非常显著(P<0.01),而对照组治疗后TPOAb也有所下降,但TGAb反略有上升(P<0.05),2组差异非常显著(P<0.01)。结论:联用^(99)Tc-MDP、地塞米松与雷公藤多苷治疗Graves眼病疗效较好,有一定的应用前景。AIM： To evaluate the efficacy of application with combining technetium [^99Tc] methylenediphosphonate （^99Tc-MDP）, dexamasone and tripterygium glucosides in the treatment of Graves ophthalmopathy. METHODS： Sixty patients with Graves ophthalmopathy were randomly divided into trial group and control group with 30 patients for each. Based on anti-thyroid drug, the patients in the trial group accepted ^99Tc-MDP 22 mg intravenous drip qd, for 10 days as a courses with an interval of 1 wk and totally 3 courses. Simultaneously, the patients in the trial group accepted dexamasone 0.75 mg and tripterygium glucosides 10 mg tid for 3 mo. While those patients in the control group only accepted anti-thyroid drug with the same courses. RESULTS： The total efficacy rates were 87 % and 47 % in the trial and control group, showing significant difference clinically between the two groups （P 〈 0.01） . After treatment, the levels of FT3 and FT4 decreased conspicuously both in trial and control groups （P 〈 0.01 ）, especially in trial group with a significant difference from that of the control group （P 〈 0.01）. TGAb and TPOAb in trial group decreased remarkably in comparison with those before the treatment （P 〈 0.01 ） . But in the control group, TGAb decreased with simultaneous TPOAb increase a little in comparison with those before the treatment （P 〈 0.05） ; showing significant difference between the two groups （P 〈 0.01）. CONCLUSION：^99Tc-MDP combined with dexamasone and tripterygium glucosides is effective in the treatment of Graves ophthalmopathy providing a good future prospectively.

关 键 词：格雷夫斯病 甲状腺功能亢进症 地塞米松 锝[^99Tc]亚甲基二磷酸盐 雷公藤多苷 

分 类 号：R581.1[医药卫生—内分泌]